Sleep Disorders

>

Latest News

FDA Approves Tirzepatide as First Drug for Obstructive Sleep Apnea with Obesity
FDA Approves Tirzepatide as First Drug for Obstructive Sleep Apnea with Obesity

December 20th 2024

This marks the second indication for tirzepatide in just more than a year, following its November 2023 approval for adults with obesity or overweight and weight-related medical problems.

Role of Sleep in Dementia and Associated Comorbidities: Daily Dose / image credit: ©New Africa/AdobeStock
Role of Sleep in Dementia and Associated Comorbidities: Daily Dose

December 13th 2024

New Review Highlights Need to Address Sleep Disturbances in Patients with Dementia / Image credit: ©netrun78/AdobeStock
New Review Highlights Need to Address Sleep Disturbances in Patients with Dementia

December 2nd 2024

Sex-Specific Dementia Risk in Older Adults with OSA: Daily Dose / image credit: ©New Africa/AdobeStock
Sex-Specific Dementia Risk in Older Adults with OSA: Daily Dose

November 26th 2024

SURMOUNT-OSA: Tirzepatide Improves Sleep Apnea Symptoms, CV Outcomes in Adults with OSA and Obesity / Image credit: ©motortion/AdobeStock
SURMOUNT-OSA: Tirzepatide Improves Sleep Apnea Symptoms, CV Outcomes in Adults with OSA and Obesity

June 24th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.